BOONTON, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE http://www.unigene.com) has initiated a Phase I clinical study in the U.S. with its proprietary formulation of oral PTH for the treatment of osteoporosis. Twenty-four healthy postmenopausal women have been enrolled in the study, which is designed to assess product safety and measure PTH blood levels at varying doses. The dosing is scheduled to be completed this month and the data analysis is expected to be completed before year end.
